Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
Alternative eradication therapies for Helicobacter pylori infection are needed because of an increasing failure rate over the past decade. The aim of this study was to determine if vonoprazan, a new potassium-competitive acid blocker, showed superiority to existing proton pump inhibitors for primary...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-05-01
|
Series: | Kaohsiung Journal of Medical Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1607551X16300304 |
id |
doaj-c340fa839a0549999c71958ad5c47e64 |
---|---|
record_format |
Article |
spelling |
doaj-c340fa839a0549999c71958ad5c47e642020-11-25T01:13:23ZengWileyKaohsiung Journal of Medical Sciences1607-551X2016-05-0132525526010.1016/j.kjms.2016.04.009Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pyloriSatoshi Shinozaki0Hiroaki Nomoto1Yoshie Kondo2Hirotsugu Sakamoto3Yoshikazu Hayashi4Hironori Yamamoto5Alan Kawarai Lefor6Hiroyuki Osawa7Shinozaki Medical Clinic, Utsunomiya, JapanDepartment of Gastroenterology, Haga Red Cross Hospital, Moka, JapanDepartment of Gastroenterology, Haga Red Cross Hospital, Moka, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, JapanDepartment of Surgery, Jichi Medical University, Shimotsuke, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, JapanAlternative eradication therapies for Helicobacter pylori infection are needed because of an increasing failure rate over the past decade. The aim of this study was to determine if vonoprazan, a new potassium-competitive acid blocker, showed superiority to existing proton pump inhibitors for primary eradication of H. pylori in routine clinical practice. Data for 573 patients who underwent primary H. pylori eradication therapy were retrospectively reviewed. Regimens included clarithromycin 200 mg, amoxicillin 750 mg, and an acid-suppressing drug [lansoprazole 30 mg (LAC), rabeprazole 10 mg (RAC), esomeprazole 20 mg (EAC), or vonoprazan 20 mg (VAC)] twice daily for 1 week. Eradication was successful in 73% (419/573) of patients using intention-to-treat (ITT) analysis and 76% (419/549) of patients in per-protocol (PP) analysis. The VAC group had a significantly superior eradication rate compared with the LAC and RAC groups in ITT (VAC 83%, LAC 66% and RAC 67%, p < 0.01) and PP analysis (VAC 85%, LAC 69% and RAC 70%, p < 0.01), and had a similarly high eradication rate to the EAC group (83% in ITT and 87% in PP). Although the eradication rate in the VAC and EAC groups was not significantly higher than in the LAC and RAC groups in patients with mild gastric atrophy with both ITT and PP analyses, it was significantly higher in patients with severe gastric atrophy (p < 0.01). The VAC group had a significantly higher H. pylori eradication rate than the LAC and RAC groups, and a > 80% eradication rate regardless of the degree of atrophy.http://www.sciencedirect.com/science/article/pii/S1607551X16300304AntibioticsGastric acidHelicobacter pyloriProton pump inhibitorsTreatment outcome |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Satoshi Shinozaki Hiroaki Nomoto Yoshie Kondo Hirotsugu Sakamoto Yoshikazu Hayashi Hironori Yamamoto Alan Kawarai Lefor Hiroyuki Osawa |
spellingShingle |
Satoshi Shinozaki Hiroaki Nomoto Yoshie Kondo Hirotsugu Sakamoto Yoshikazu Hayashi Hironori Yamamoto Alan Kawarai Lefor Hiroyuki Osawa Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori Kaohsiung Journal of Medical Sciences Antibiotics Gastric acid Helicobacter pylori Proton pump inhibitors Treatment outcome |
author_facet |
Satoshi Shinozaki Hiroaki Nomoto Yoshie Kondo Hirotsugu Sakamoto Yoshikazu Hayashi Hironori Yamamoto Alan Kawarai Lefor Hiroyuki Osawa |
author_sort |
Satoshi Shinozaki |
title |
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori |
title_short |
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori |
title_full |
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori |
title_fullStr |
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori |
title_full_unstemmed |
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori |
title_sort |
comparison of vonoprazan and proton pump inhibitors for eradication of helicobacter pylori |
publisher |
Wiley |
series |
Kaohsiung Journal of Medical Sciences |
issn |
1607-551X |
publishDate |
2016-05-01 |
description |
Alternative eradication therapies for Helicobacter pylori infection are needed because of an increasing failure rate over the past decade. The aim of this study was to determine if vonoprazan, a new potassium-competitive acid blocker, showed superiority to existing proton pump inhibitors for primary eradication of H. pylori in routine clinical practice. Data for 573 patients who underwent primary H. pylori eradication therapy were retrospectively reviewed. Regimens included clarithromycin 200 mg, amoxicillin 750 mg, and an acid-suppressing drug [lansoprazole 30 mg (LAC), rabeprazole 10 mg (RAC), esomeprazole 20 mg (EAC), or vonoprazan 20 mg (VAC)] twice daily for 1 week. Eradication was successful in 73% (419/573) of patients using intention-to-treat (ITT) analysis and 76% (419/549) of patients in per-protocol (PP) analysis. The VAC group had a significantly superior eradication rate compared with the LAC and RAC groups in ITT (VAC 83%, LAC 66% and RAC 67%, p < 0.01) and PP analysis (VAC 85%, LAC 69% and RAC 70%, p < 0.01), and had a similarly high eradication rate to the EAC group (83% in ITT and 87% in PP). Although the eradication rate in the VAC and EAC groups was not significantly higher than in the LAC and RAC groups in patients with mild gastric atrophy with both ITT and PP analyses, it was significantly higher in patients with severe gastric atrophy (p < 0.01). The VAC group had a significantly higher H. pylori eradication rate than the LAC and RAC groups, and a > 80% eradication rate regardless of the degree of atrophy. |
topic |
Antibiotics Gastric acid Helicobacter pylori Proton pump inhibitors Treatment outcome |
url |
http://www.sciencedirect.com/science/article/pii/S1607551X16300304 |
work_keys_str_mv |
AT satoshishinozaki comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori AT hiroakinomoto comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori AT yoshiekondo comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori AT hirotsugusakamoto comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori AT yoshikazuhayashi comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori AT hironoriyamamoto comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori AT alankawarailefor comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori AT hiroyukiosawa comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori |
_version_ |
1725162722402762752 |